Furthermore, we found that CH associated with multiple-hit TET2 (defined as ≥2 pathogenic TET2 mutations with VAFs of ≥15%) is an independent risk factor for development of concurrent hematologic malignancies in AITL patients (Figure 4). Here, TET2 is linked to angioimmunoblastic T-cell lymphoma.